Skip to main content

Advertisement

SpringerLink
Log in

Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

  • Review
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Transgender and gender diverse (TGD) populations with hereditary cancer syndromes face unique obstacles to identifying and obtaining appropriate cancer surveillance and risk-reducing procedures. There is a lack of care provider knowledge about TGD health management. Lynch syndrome (LS) is one of the most common hereditary cancer syndromes, affecting an estimated 1 in 279 individuals. There are no clinical guidelines specific for TGD individuals with LS, highlighting a need to improve the quality of care for this population. There is an urgent need for cancer surveillance recommendations for TGD patients. This commentary provides recommendations for cancer surveillance, risk-reducing strategies, and genetic counseling considerations for TGD patients with LS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coleman E, Radix AE, Bouman WP et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Trans Health 23(Suppl 1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644

    Article  CAS  Google Scholar 

  2. Herman JL, Flores AR, O’Neill KK (2022) How Many Adults and Youth Identify as Transgender in the United States?

  3. Obedin-Maliver J, Goldsmith ES, Stewart L et al (2011) Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. JAMA. https://doi.org/10.1001/jama.2011.1255

    Article  PubMed  Google Scholar 

  4. Dahlhamer JM, Galinsky AM, Joestl SS, Ward BW (2016) Barriers to health care among adults identifying as sexual minorities: a US national study. Am J Public Health 106(6):1116–1122. https://doi.org/10.2105/AJPH.2016.303049

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lerner JE, Robles G (2017) Perceived barriers and facilitators to health care utilization in the United States for transgender people: a review of recent literature. J Health Care Poor Underserved 28(1):127–152. https://doi.org/10.1353/hpu.2017.0014

    Article  PubMed  Google Scholar 

  6. Roznovjak D, Petroll AE, Lakatos AEB, Narayan R, Cortina CS (2023) Perceptions of transgender and nonbinary persons toward breast and cervical cancer development, screening, and potential impact on gender-affirming hormone therapy. JCO Oncol Pract 19(5):e794–e800. https://doi.org/10.1200/OP.22.00681

    Article  PubMed  Google Scholar 

  7. Kiran T, Davie S, Singh D et al (2019) Cancer screening rates among transgender adults: cross-sectional analysis of primary care data. Can Family Phys MEDECIN de famille canadien 65(1):e30–e37

    Google Scholar 

  8. Oladeru OT, Ma SJ, Miccio JA et al (2022) Breast and cervical cancer screening disparities in transgender people. Am J Clin Oncol 45(3):116–121. https://doi.org/10.1097/COC.0000000000000893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luehmann N, Ascha M, Chwa E et al (2022) A single-center study of adherence to breast cancer screening mammography guidelines by transgender and non-binary patients. Ann Surg Oncol 29(3):1707–1717. https://doi.org/10.1245/s10434-021-10932-z

    Article  PubMed  Google Scholar 

  10. National Academies of Sciences Engineering and Medicine (2020). In: White J, Sepulveda MJ, Patterson CJ (eds) Understanding the well-being of lgbtqi populations the national academies collection: reports funded by national institutes of health. The National Academies Press, Washington

    Google Scholar 

  11. Jackson SS, Han X, Mao Z et al (2021) Cancer stage, treatment, and survival among transgender patients in the United States. J Natl Cancer Inst 113(9):1221–1227. https://doi.org/10.1093/jnci/djab028

    Article  PubMed  PubMed Central  Google Scholar 

  12. Griggs J, Maingi S, Blinder V et al (2017) American society of clinical oncology position statement: strategies for reducing cancer health disparities among sexual and gender minority populations. J Clin Oncol 35(19):2203–2208. https://doi.org/10.1200/JCO.2016.72.0441

    Article  PubMed  Google Scholar 

  13. Sakradse M, Zhu S, Ritterman Weintraub M, Jung J, Zaritsky E (2022) Hereditary breast and ovarian cancer genetic risk: screening and treatment among transgender and gender diverse patients. Perm J 26(3):30–38. https://doi.org/10.7812/TPP/21.133

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bedrick BS, Fruhauf TF, Martin SJ, Ferriss JS (2021) Creating breast and gynecologic cancer guidelines for transgender patients with BRCA mutations. Obstet Gynecol 138(6):911–917. https://doi.org/10.1097/AOG.0000000000004597

    Article  PubMed  Google Scholar 

  15. Pearlman R, Frankel WL, Swanson BJ et al (2021) Prospective statewide study of universal screening for hereditary colorectal cancer: the ohio colorectal cancer prevention initiative. JCO Precision Oncol. https://doi.org/10.1200/PO.20.00525

    Article  Google Scholar 

  16. Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ (2019) The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med 21(10):2167–2180. https://doi.org/10.1038/s41436-019-0536-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ligtenberg MJL, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N (2013) EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 12(2):169–174. https://doi.org/10.1007/s10689-012-9591-x

    Article  CAS  PubMed  Google Scholar 

  18. Win AK, Jenkins MA, Dowty JG et al (2017) Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev 26(3):404–412. https://doi.org/10.1158/1055-9965.EPI-16-0693

    Article  CAS  Google Scholar 

  19. Møller P, Seppälä TT, Bernstein I et al (2018) Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut 67(7):1306–1316. https://doi.org/10.1136/gutjnl-2017-314057

    Article  PubMed  Google Scholar 

  20. Dominguez-Valentin M, Haupt S, Seppala TT et al (2023) Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine 58:101909. https://doi.org/10.1016/j.eclinm.2023.101909

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gupta S, Weiss JM, Burke CA, et al. (2022) NCCN Guidelines Version 2.2022 Genetic/Familial High-Risk Assessment: Colorectal. https://www.nccn.org/home/

  22. Safer JD, Tangpricha V (2019) Care of the transgender patient. Annals Internal Med. https://doi.org/10.7326/AITC201907020

    Article  Google Scholar 

  23. Hembree WC, Cohen-Kettenis PT, Gooren L et al (2017) Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658

    Article  PubMed  Google Scholar 

  24. Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA (2021) Hormone therapy, mental health, and quality of life among transgender people: a systematic review. J Endocr Soc. https://doi.org/10.1210/jendso/bvab011

    Article  PubMed  PubMed Central  Google Scholar 

  25. Masumori N, Baba T, Abe T, Niwa K (2021) What is the most anticipated change induced by treatment using gender-affirming hormones in individuals with gender incongruence? Int J Urol 28(5):526–529. https://doi.org/10.1111/iju.14499

    Article  CAS  PubMed  Google Scholar 

  26. Irwig MS (2017) Testosterone therapy for transgender men. Lancet Diabetes Endocrinol 5(4):301–311. https://doi.org/10.1016/S2213-8587(16)00036-X

    Article  CAS  PubMed  Google Scholar 

  27. Schechter LS, Safa B (2018) Gender surgery: a truly multidisciplinary field. Clin Plastic Surg. https://doi.org/10.1016/j.cps.2018.05.001

    Article  Google Scholar 

  28. de Blok CJM, Klaver M, Wiepjes CM et al (2018) breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab 103(2):532–538. https://doi.org/10.1210/jc.2017-01927

    Article  PubMed  Google Scholar 

  29. Cocchetti C, Ristori J, Romani A, Maggi M, Fisher AD (2020) Hormonal Treatment strategies tailored to non-binary transgender individuals. J Clin Med. https://doi.org/10.3390/jcm9061609

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fernandez E, La Vecchia C, Braga C et al (1998) Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 7(4):329–333

    CAS  PubMed  Google Scholar 

  31. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB (2009) Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 27(27):4542–4547. https://doi.org/10.1200/JCO.2009.22.0764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Johnson JR, Lacey JV Jr, Lazovich D et al (2009) Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18(1):196–203. https://doi.org/10.1158/1055-9965.EPI-08-0596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Jang YC, Huang HL, Leung CY (2019) Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer 19(1):1199. https://doi.org/10.1186/s12885-019-6428-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M (2017) Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer 117(11):1702–1710. https://doi.org/10.1038/bjc.2017.348

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kim J, Braun D, Ukaegbu C et al (2020) Clinical factors associated with gastric cancer in individuals with lynch syndrome. Clin Gastroenterol Hepatol 18(4):830–7.e1. https://doi.org/10.1016/j.cgh.2019.07.012

    Article  CAS  PubMed  Google Scholar 

  36. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. https://doi.org/10.1038/ajg.2014.435

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lopez DS, Malagaris I, Polychronopoulou E et al (2022) Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men. Clin Endocrinol 97(6):792–803. https://doi.org/10.1111/cen.14803

    Article  CAS  Google Scholar 

  38. Liu Q, Simin J, Debelius J et al (2021) Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study. Aliment Pharmacol Ther 53(11):1216–1225. https://doi.org/10.1111/apt.16362

    Article  CAS  PubMed  Google Scholar 

  39. Bosetti C, Bravi F, Negri E, La Vecchia C (2009) Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 15(5):489–498. https://doi.org/10.1093/humupd/dmp017

    Article  PubMed  Google Scholar 

  40. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004. https://doi.org/10.1056/NEJMoa032071

    Article  CAS  PubMed  Google Scholar 

  41. Lin KJ, Cheung WY, Lai JY-C, Giovannucci EL (2012) The effect of estrogen vs. Combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419–430. https://doi.org/10.1002/ijc.26026

    Article  CAS  PubMed  Google Scholar 

  42. Kita Y, Mori S, Baba K et al (2015) Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40 years after its creation: a case report. World J Surg Oncol 13:213. https://doi.org/10.1186/s12957-015-0636-0

    Article  PubMed  PubMed Central  Google Scholar 

  43. Yamada K, Shida D, Kato T, Yoshida H, Yoshinaga S, Kanemitsu Y (2018) Adenocarcinoma arising in sigmoid colon neovagina 53 years after construction. World J Surg Oncol 16(1):88. https://doi.org/10.1186/s12957-018-1372-z

    Article  PubMed  PubMed Central  Google Scholar 

  44. Sun XF, Miao XX, Li BX, Wang Y (2022) Cervical and endometrial cancers of intestinal origin diagnosed 18 years after vaginal replacement with a sigmoid colon segment: a case report and review of the literature. Front Oncol. https://doi.org/10.3389/fonc.2022.912236

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lu KH, Broaddus RR (2005) Gynecologic cancers in Lynch Syndrome/HNPCC. Fam Cancer 4(3):249–254. https://doi.org/10.1007/s10689-005-1838-3

    Article  PubMed  Google Scholar 

  46. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994) The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96(6):516–520. https://doi.org/10.1016/0002-9343(94)90091-4

    Article  CAS  PubMed  Google Scholar 

  47. Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1(1):57–60. https://doi.org/10.1023/a:1011590617833

    Article  CAS  PubMed  Google Scholar 

  48. Futterweit W, Deligdisch L (1986) Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 62(1):16–21. https://doi.org/10.1210/jcem-62-1-16

    Article  CAS  PubMed  Google Scholar 

  49. Stenzel AE, Moysich KB, Ferrando CA, Starbuck KD (2020) Clinical needs for transgender men in the gynecologic oncology setting. Gynecol Oncol 159(3):899–905. https://doi.org/10.1016/j.ygyno.2020.09.038

    Article  PubMed  PubMed Central  Google Scholar 

  50. Asseler JD, Caanen MR, Verhoeven MO et al (2022) Endometrial thickness assessed by transvaginal ultrasound in transmasculine people taking testosterone compared with cisgender women. Reprod Biomed Online 45(5):1033–1038. https://doi.org/10.1016/j.rbmo.2022.06.012

    Article  CAS  PubMed  Google Scholar 

  51. Grimstad FW, Fowler KG, New EP et al (2019) Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2018.12.021

    Article  PubMed  Google Scholar 

  52. Hawkins M, Deutsch MB, Obedin-Maliver J et al (2021) Endometrial findings among transgender and gender nonbinary people using testosterone at the time of gender-affirming hysterectomy. Fertil Steril 115(5):1312–1317. https://doi.org/10.1016/j.fertnstert.2020.11.008

    Article  CAS  PubMed  Google Scholar 

  53. Rachlin K, Green J, Lombardi E (2008) Utilization of health care among female-to-male transgender individuals in the United States. J Homosex 54(3):243–258. https://doi.org/10.1080/00918360801982124

    Article  PubMed  Google Scholar 

  54. Pelusi C, Costantino A, Martelli V et al (2014) Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 11(12):3002–3011. https://doi.org/10.1111/jsm.12698

    Article  PubMed  Google Scholar 

  55. Grimstad F, Kremen J, Shim J, Charlton BM, Boskey ER (2021) Breakthrough bleeding in transgender and gender diverse adolescents and young adults on long-term testosterone. J Pediatr Adolesc Gynecol 34(5):706–716. https://doi.org/10.1016/j.jpag.2021.04.004

    Article  PubMed  Google Scholar 

  56. Bobola A, Gorzelak-Magiera A, Steinhof-Radwańska K, Lorek A, Kliber M, Gisterek I (2021) Genetically burdened transgender man during gender reassignment process with two primary neoplasms: a case report. Oncology in Clinical Practice 17(4):183–186. https://doi.org/10.5603/OCP.2021.0009

    Article  Google Scholar 

  57. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S (2012) Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 19(6):R255–R279. https://doi.org/10.1530/ERC-12-0175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Aubrey C, Saad N, Kobel M, Mattatall F, Nelson G, Glaze S (2021) Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. Gynecol Oncol 161(2):342–346. https://doi.org/10.1016/j.ygyno.2021.02.019

    Article  PubMed  Google Scholar 

  59. Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189(1):280–294. https://doi.org/10.1067/mob.2003.408

    Article  PubMed  Google Scholar 

  60. Grimstad FW, Fowler KG, New EP et al (2020) Ovarian histopathology in transmasculine persons on testosterone: a multicenter case series. J Sex Med 17(9):1807–1818. https://doi.org/10.1016/j.jsxm.2020.05.029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Taylor ET, Bryson MK (2016) Cancer’s margins: trans* and gender nonconforming people’s access to knowledge, experiences of cancer health, and decision-making. LGBT Health 3(1):79–89. https://doi.org/10.1089/lgbt.2015.0096

    Article  PubMed  PubMed Central  Google Scholar 

  62. Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E (2000) Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol 76(3):413–415. https://doi.org/10.1006/gyno.1999.5720

    Article  CAS  PubMed  Google Scholar 

  63. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO (2006) Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 62(4):226–228. https://doi.org/10.1159/000094097

    Article  PubMed  Google Scholar 

  64. Ferreira C, Fraga J, Antunes C, Goncalo M, Donato P (2021) Serous borderline tumor in transgender female-to-male individuals: a case report of androgen receptor-positive ovarian cancer. Case Rep Radiol 2021:8861692. https://doi.org/10.1155/2021/8861692

    Article  PubMed  PubMed Central  Google Scholar 

  65. Millington K, Hayes K, Pilcher S et al (2021) A serous borderline ovarian tumour in a transgender male adolescent. Br J Cancer 124(3):567–569. https://doi.org/10.1038/s41416-020-01129-4

    Article  PubMed  Google Scholar 

  66. Chene G, Rahimi K, Mes-Masson AM, Provencher D (2013) Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol 20(2):153–159. https://doi.org/10.1016/j.jmig.2012.11.010

    Article  PubMed  Google Scholar 

  67. Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA (2013) Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer 23(3):417–421. https://doi.org/10.1097/IGC.0b013e3182849dba

    Article  PubMed  Google Scholar 

  68. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116(6):1453–1456. https://doi.org/10.1016/s0016-5085(99)70510-x

    Article  CAS  PubMed  Google Scholar 

  69. Skeldon SC, Semotiuk K, Aronson M et al (2013) Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 63(2):379–385. https://doi.org/10.1016/j.eururo.2012.07.047

    Article  CAS  PubMed  Google Scholar 

  70. van der Post RS, Kiemeney LA, Ligtenberg MJ et al (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47(7):464–470. https://doi.org/10.1136/jmg.2010.076992

    Article  PubMed  Google Scholar 

  71. Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M (2015) Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 86(6):1212–1217. https://doi.org/10.1016/j.urology.2015.08.018

    Article  PubMed  Google Scholar 

  72. Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M (2017) Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev 39(1):93–107. https://doi.org/10.1093/epirev/mxw003

    Article  PubMed  PubMed Central  Google Scholar 

  73. Siegel R, Naishadham D (2012) Jemal A (2012) cancer statistics. CA Cancer J Clin 62(1):10–29. https://doi.org/10.3322/caac.20138

    Article  PubMed  Google Scholar 

  74. Shariat SF, Favaretto RL, Gupta A et al (2011) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 29(4):481–486. https://doi.org/10.1007/s00345-010-0594-7

    Article  PubMed  Google Scholar 

  75. Buchting FO, Emory KT, Scout, et al (2017) Transgender use of cigarettes, cigars, and e-cigarettes in a national study. Am J Prev Med 53(1):e1–e7. https://doi.org/10.1016/j.amepre.2016.11.022

    Article  PubMed  PubMed Central  Google Scholar 

  76. D’Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J (1995) Attributable risks for bladder cancer in northern Italy. Ann Epidemiol 5(6):427–431. https://doi.org/10.1016/1047-2797(95)00057-7

    Article  CAS  PubMed  Google Scholar 

  77. Hartge P, Silverman D, Hoover R et al (1987) Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 78(6):1119–1125

    CAS  PubMed  Google Scholar 

  78. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737–745. https://doi.org/10.1001/jama.2011.1142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Hartge P, Harvey EB, Linehan WM et al (1990) Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 82(20):1636–1640. https://doi.org/10.1093/jnci/82.20.1636

    Article  CAS  PubMed  Google Scholar 

  80. Dobruch J, Daneshmand S, Fisch M et al (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69(2):300–310. https://doi.org/10.1016/j.eururo.2015.08.037

    Article  PubMed  Google Scholar 

  81. Kwon H, Schafer JM, Song NJ et al (2022) Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. https://doi.org/10.1126/sciimmunol.abq2630

    Article  PubMed  PubMed Central  Google Scholar 

  82. Lutz CT, Livas L, Presnell SR, Sexton M, Wang P (2021) Gender differences in urothelial bladder cancer: effects of natural killer lymphocyte immunity. J Clin Med: https://doi.org/10.3390/jcm10215163

    Article  PubMed  PubMed Central  Google Scholar 

  83. Kaneko S, Li X (2018) X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci Adv. https://doi.org/10.1126/sciadv.aar5598

    Article  PubMed  PubMed Central  Google Scholar 

  84. Grindedal EM, Moller P, Eeles R et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18(9):2460–2467. https://doi.org/10.1158/1055-9965.EPI-09-0058

    Article  CAS  PubMed  Google Scholar 

  85. Dominguez-Valentin M, Sampson JR, Seppala TT et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective lynch syndrome database. Genet Med 22(1):15–25. https://doi.org/10.1038/s41436-019-0596-9

    Article  CAS  PubMed  Google Scholar 

  86. Rosty C, Walsh MD, Lindor NM et al (2014) High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam Cancer 13(4):573–582. https://doi.org/10.1007/s10689-014-9744-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Dominguez-Valentin M, Joost P, Therkildsen C, Jonsson M, Rambech E, Nilbert M (2016) Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol 16:15. https://doi.org/10.1186/s12894-016-0130-1

    Article  PubMed  PubMed Central  Google Scholar 

  88. Ingham MD, Lee RJ, MacDermed D, Olumi AF (2018) Prostate cancer in transgender women. Urol Oncol 36(12):518–525. https://doi.org/10.1016/j.urolonc.2018.09.011

    Article  PubMed  Google Scholar 

  89. Deebel NA, Morin JP, Autorino R, Vince R, Grob B, Hampton LJ (2017) Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology 110:166–171. https://doi.org/10.1016/j.urology.2017.08.032

    Article  PubMed  Google Scholar 

  90. Gooren L, Morgentaler A (2014) Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46(10):1156–1160. https://doi.org/10.1111/and.12208

    Article  CAS  PubMed  Google Scholar 

  91. Joint R, Chen ZE, Cameron S (2018) Breast and reproductive cancers in the transgender population: a systematic review. BJOG 125(12):1505–1512. https://doi.org/10.1111/1471-0528.15258

    Article  CAS  PubMed  Google Scholar 

  92. Weyers S, De Sutter P, Hoebeke S et al (2010) Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views Vis Obgyn 2(1):35–54

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Crowley F, Mihalopoulos M, Gaglani S et al (2023) Prostate cancer in transgender women: considerations for screening, diagnosis and management. Br J Cancer 128(2):177–189. https://doi.org/10.1038/s41416-022-01989-y

    Article  PubMed  Google Scholar 

  94. Buerki N, Gautier L, Kovac M et al (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 51(1):83–91. https://doi.org/10.1002/gcc.20935

    Article  CAS  PubMed  Google Scholar 

  95. Harkness EF, Barrow E, Newton K et al (2015) Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet 52(8):553–556. https://doi.org/10.1136/jmedgenet-2015-103216

    Article  CAS  PubMed  Google Scholar 

  96. Roberts ME, Jackson SA, Susswein LR et al (2018) MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med 20(10):1167–1174. https://doi.org/10.1038/gim.2017.254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupfer SS (2020) No evidence of increased risk of breast cancer in women with lynch syndrome identified by multigene panel testing. JCO Precis Oncol 4:51–60. https://doi.org/10.1200/PO.19.00271

    Article  PubMed  Google Scholar 

  98. Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440–451. https://doi.org/10.1056/NEJMoa2005936

    Article  PubMed  PubMed Central  Google Scholar 

  99. Slavin TP, Maxwell KN, Lilyquist J et al (2017) The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3:22. https://doi.org/10.1038/s41523-017-0024-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198. https://doi.org/10.1007/s10549-014-3213-2

    Article  PubMed  Google Scholar 

  101. Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 10(12):3129–3134. https://doi.org/10.1111/jsm.12319

    Article  PubMed  Google Scholar 

  102. de Blok CJM, Wiepjes CM, Nota NM et al (2019) Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. https://doi.org/10.1136/bmj.l1652

    Article  PubMed  PubMed Central  Google Scholar 

  103. Deutsch MB, (Ed.) (2016) Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. https://transcare.ucsf.edu/guidelines

  104. Makadon H, Potter J, Mayer K, Goldhammer H (eds) (2015) The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health, 2nd edn. American College of Physicians, Philadelphia

    Google Scholar 

  105. Parikh U, Mausner E, Chhor CM, Gao Y, Karrington I, Heller SL (2020) Breast imaging in transgender patients: what the radiologist should know. Radiographics 40(1):13–27. https://doi.org/10.1148/rg.2020190044

    Article  PubMed  Google Scholar 

  106. University Hospitals (2018) Transgender Breast Cancer Screenings. https://www.uhhospitals.org/services/cancer-services/breast-cancer/transgender-breast-screenings

  107. Expert Panel on Breast Imaging, Brown A, Lourenco AP et al (2021) ACR Appropriateness criteria(R) transgender breast cancer screening. J Am Coll Radiol 18(11S):S502–S515. https://doi.org/10.1016/j.jacr.2021.09.005

    Article  Google Scholar 

  108. Ren W, Chen M, Qiao Y, Zhao F (2022) Global guidelines for breast cancer screening: a systematic review. Breast 64:85–99. https://doi.org/10.1016/j.breast.2022.04.003

    Article  PubMed  PubMed Central  Google Scholar 

  109. Rolle L, Zayhowski K, Koeller D, Chiluiza D, Carmichael N (2022) Transgender patients’ perspectives on their cancer genetic counseling experiences. J Genet Couns 31(3):781–791. https://doi.org/10.1002/jgc4.1544

    Article  PubMed  Google Scholar 

  110. Zayhowski K, Park J, Boehmer U, Gabriel C, Berro T, Campion M (2019) Cancer genetic counselors’ experiences with transgender patients: a qualitative study. J Genet Couns. https://doi.org/10.1002/jgc4.1092

    Article  PubMed  Google Scholar 

  111. Kano M, Jaffe SA, Rieder S et al (2022) Improving sexual and gender minority cancer care: patient and caregiver perspectives from a multi-methods pilot study. Front Oncol. https://doi.org/10.3389/fonc.2022.833195

    Article  PubMed  PubMed Central  Google Scholar 

  112. Obedin-Maliver J, de Haan G (2017) Gynecologic care for transgender adults. Curre Obstet Gynecol Rep 6(2):140–148. https://doi.org/10.1007/s13669-017-0204-4

    Article  Google Scholar 

  113. The GLBT Health Access Project (1997) Community Standards of Practice for the Provision of Quality Health Care Services for Gay, Lesbian, Bisexual and Transgendered Clients. http://www.glbthealth.org/CommunityStandardsofPractice.htm

  114. Grasso C, Goldhammer H, Funk D et al (2019) Required sexual orientation and gender identity reporting by us health centers: first-year data. Am J Public Health 109(8):1111–1118. https://doi.org/10.2105/AJPH.2019.305130

    Article  PubMed  PubMed Central  Google Scholar 

  115. Streed CG Jr, Grasso C, Reisner SL, Mayer KH (2020) Sexual orientation and gender identity data collection: clinical and public health importance. Am J Public Health 110(7):991–993. https://doi.org/10.2105/ajph.2020.305722

    Article  PubMed Central  Google Scholar 

  116. Alpert AB, Mehringer JE, Orta SJ et al (2022) Experiences of transgender people reviewing their electronic health records, a qualitative study. J Gen Intern Med. https://doi.org/10.1007/s11606-022-07671-6

    Article  PubMed  PubMed Central  Google Scholar 

  117. Bennett RL, French KS, Resta RG, Austin J (2022) Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: a practice resource of the national society of genetic counselors. J Genet Couns 31(6):1238–1248. https://doi.org/10.1002/jgc4.1621

    Article  PubMed  Google Scholar 

  118. Pritchard D, Goodman C, Nadauld LD (2022) Clinical utility of genomic testing in cancer care. JCO Precis Oncol. https://doi.org/10.1200/PO.21.00349

    Article  PubMed  PubMed Central  Google Scholar 

  119. National Society of Genetic Counselors (2018) Genetic Testing of Minors for Adult-Onset Conditions. https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements/Position-Statements/Post/genetic-testing-of-minors-for-adult-onset-conditions

  120. Holter S, Hall MJ, Hampel H et al (2022) Risk assessment and genetic counseling for Lynch syndrome–practice resource of the national society of genetic counselors and the collaborative group of the americas on inherited gastrointestinal cancer. J Genet Couns 31(3):568–583. https://doi.org/10.1002/jgc4.1546

    Article  PubMed  Google Scholar 

  121. Baram S, Myers SA, Yee S, Librach CL (2019) Fertility preservation for transgender adolescents and young adults: a systematic review. Hum Reprod Update 25(6):694–716. https://doi.org/10.1093/humupd/dmz026

    Article  CAS  PubMed  Google Scholar 

  122. Mayhew AC, Gomez-Lobo V (2020) Fertility options for the transgender and gender nonbinary patient. J Clin Endocrinol Metab 105(10):3335–3345. https://doi.org/10.1210/clinem/dgaa529

    Article  PubMed  PubMed Central  Google Scholar 

  123. The American College of Obstetricians and Gynecologists (2018) ACOG Committee opinion No. 749: marriage and family building equality for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and gender nonconforming individuals. Obstet Gynecol. https://doi.org/10.1097/AOG.0000000000002765

    Article  Google Scholar 

  124. Rich TA, Liu M, Etzel CJ et al (2014) Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291–299. https://doi.org/10.1007/s10689-013-9685-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Fesahat F, Montazeri F, Hoseini SM (2020) Preimplantation genetic testing in assisted reproduction technology. J Gynecol Obstet Hum Reprod 49(5):101723. https://doi.org/10.1016/j.jogoh.2020.101723

    Article  PubMed  Google Scholar 

  126. Grimstad F, Boskey ER, Taghinia A, Ganor O (2021) Gender-affirming surgeries in transgender and gender diverse adolescent and young adults: a pediatric and adolescent gynecology primer. J Pediatr Adolesc Gynecol 34(4):442–448. https://doi.org/10.1016/j.jpag.2021.03.014

    Article  PubMed  Google Scholar 

  127. Center for Substance Abuse Treatment (US) (2014) Trauma-Informed Care in Behavioral Health Services. Rockville (MD). Treatment Improvement Protocol (TIP) Series, No. 57. Substance Abuse and Mental Health Services Administration (US);. https://www.ncbi.nlm.nih.gov/books/NBK207201/

  128. Iwamoto SJ, Defreyne J, Rothman MS et al (2019) Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 10:2042018819871166. https://doi.org/10.1177/2042018819871166

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Steve Muir and Emerson Brogdon-Soster for their valuable review of this manuscript. The authors would like to thank Hannah Pepprock for creating a set of resources for providers caring for TGD patients.

Funding

No funding was received to assist with the preparation of this manuscript.

Author information

Author notes

  1. Rachel Hodan, Linda Rodgers-Fouche and Anu Chittenden have contributed equally to this work.

Authors and Affiliations

  1. Cancer Genetics, Stanford Health Care and Department of Pediatrics (Genetics), Stanford University School of Medicine, Palo Alto, CA, USA

    Rachel Hodan

  2. Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, MA, USA

    Linda Rodgers-Fouche

  3. Division of Cancer Genetics and Prevention, Dana Farber Cancer Institute, Boston, MA, USA

    Anu Chittenden & Diane R. Koeller

  4. Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

    Mev Dominguez-Valentin

  5. Department of Gynecology and Obstetrics, Kelly Gynecologic Oncology Service, Johns Hopkins School of Medicine, Baltimore, MD, USA

    James Ferriss

  6. Division of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA, USA

    Lauren Gima

  7. Center for Transgender Health, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA

    Ole-Petter R. Hamnvik

  8. Division of Gastroenterology, City of Hope National Medical Center, Duarte, CA, USA

    Gregory E. Idos

  9. Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Kevin Kline

  10. Division of Hematology and Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA

    Jessica M. Long & Danielle McKenna

  11. Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL, USA

    Charles Muller

  12. Department of Urology, Massachusetts General Hospital, Boston, MA, USA

    Maxton Thoman & Anton Wintner

  13. Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Bronwyn S. Bedrick

Authors
  1. Rachel Hodan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda Rodgers-Fouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anu Chittenden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mev Dominguez-Valentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James Ferriss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lauren Gima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ole-Petter R. Hamnvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gregory E. Idos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kevin Kline
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Diane R. Koeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jessica M. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Danielle McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Charles Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Maxton Thoman
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Anton Wintner
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Bronwyn S. Bedrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

Contributions

The conception and design of this commentary was developed by authors LRF, AC and RH. LG, JL, CM and BB provided additional design and structure. All authors wrote one or more sections of the commentary. The first draft was edited by RH with subsequent drafts edited by MDV, LRF and AC. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rachel Hodan.

Ethics declarations

Competing interests

Authors RH, LRF, AC, MDV, JF, LG, OPRH, GI, KK, DRK, JML, DM, CM, MT, AW, BSB declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodan, R., Rodgers-Fouche, L., Chittenden, A. et al. Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Familial Cancer 22, 437–448 (2023). https://doi.org/10.1007/s10689-023-00341-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-023-00341-4

Keywords

Search

Navigation